Narrative review / 2016
Cancer cachexia affects 50% to 80% of cancer patients, causing skeletal muscle loss and contributing to at least 20% of cancer deaths.
Cancer patients remain among the most malnourished patient groups, with cancer cachexia (CC) affecting 50-80% of cancer patients and accounting for at least 20% of deaths. The syndrome drives skeletal muscle loss (sarcopenia) through pro-inflammatory cytokines and tumor-derived factors, occurring even with adequate food intake. Sarcopenia is present in 20-70% of patients depending on tumor type, impairing physical function, treatment tolerance, and survival. Identifying muscle loss is complicated because 40-60% of cancer patients are overweight or obese, even with metastatic disease.
- Study type
- Narrative review
- Who was studied
- Cancer patients
- What was measured
- Prevalence and clinical impacts of cancer cachexia, malnutrition, and sarcopenia
THE PAPER
Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later.
Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla Ē, Prado CM. Proc Nutr Soc, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.